New Insight on a Combination of Policosanol and 10-Dehydrogingerdione Phytochemicals as Inhibitors for Platelet Activation Biomarkers and Atherogenicity Risk in Dyslipidemic Rabbits: Role of CETP and PCSK9 Inhibition-Reference-Cited by-同舟云学术

New Insight on a Combination of Policosanol and 10-Dehydrogingerdione Phytochemicals as Inhibitors for Platelet Activation Biomarkers and Atherogenicity Risk in Dyslipidemic Rabbits: Role of CETP and PCSK9 Inhibition

Published:2018-05-09 Issue:4 Volume:186 Page:805-815
ISSN:0273-2289
Container-title:Applied Biochemistry and Biotechnology
language:en
Short-container-title:Appl Biochem Biotechnol

Author:

Elseweidy Mohamed Mahmoud,Amin Rawia sarhan,Atteia Hebatallah Husseini,El-Zeiky Reham Raafat,Al-Gabri Naif A.

Publisher

Springer Science and Business Media LLC

Subject

Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,General Medicine,Bioengineering,Biotechnology

Link

http://link.springer.com/article/10.1007/s12010-018-2776-5/fulltext.html

Reference47 articles.

1. Puttananjaiah, M. K., Dhale, M. A., Gaonkar, V., & Keni, S. (2011). Statins: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity. Applied Biochemistry and Biotechnology, 163(2), 215–222.

2. Klerkx, A. H., El Harchaoui, K., van der Steeg, W. A., Boekholdt, S. M., Stroes, E. S., Kastelein, J. J., & Kuivenhoven, J. A. (2006). Cholesteryl ester transfer protein (cetp) inhibition beyond raising high-density lipoprotein cholesterol levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(4), 706–715.

3. Vogel, R. A. (2012). PCSK9 inhibition: the next statin? Journal of the American College of Cardiology, 59(25), 2354–2355.

4. Lambert, G., Sjouke, B., Choque, B., Kastelein, J. J., & Hovingh, G. K. (2012). The PCSK9 decade. The Journal of Lipid Research, 53(12), 2515–2524.

5. Marais, A. D., Kim, J. B., Wasserman, S. M., & Lambert, G. (2015). PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacology & Therapeutics, 145, 58–66.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia;Life Sciences;2024-08

2. The role of natural products as PCSK9 modulators: A review;Phytotherapy Research;2024-06-20

3. Co-stimulators CD40-CD40L, a potential immune-therapy target for atherosclerosis: A review;Medicine;2024-04-05

4. Clinical Significance of PCSK9 and Soluble P-selectin in Predicting Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome;Cardiovascular Innovations and Applications;2024

5. The Anti-Thrombotic Effects of PCSK9 Inhibitors;Pharmaceuticals;2023-08-22